Analysts Expect Evolus Inc (EOLS) Will Announce Earnings of -$0.77 Per Share

Brokerages expect that Evolus Inc (NASDAQ:EOLS) will announce earnings of ($0.77) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Evolus’ earnings, with the lowest EPS estimate coming in at ($1.23) and the highest estimate coming in at ($0.47). Evolus posted earnings of ($0.30) per share in the same quarter last year, which suggests a negative year over year growth rate of 156.7%. The business is scheduled to report its next quarterly earnings results on Thursday, May 9th.

According to Zacks, analysts expect that Evolus will report full-year earnings of ($3.16) per share for the current fiscal year, with EPS estimates ranging from ($4.12) to ($2.45). For the next fiscal year, analysts forecast that the business will report earnings of ($1.40) per share, with EPS estimates ranging from ($1.56) to ($1.28). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Evolus.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings data on Monday, March 18th. The company reported ($0.46) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.09.

A number of analysts have recently issued reports on the company. HC Wainwright assumed coverage on Evolus in a research report on Thursday, February 14th. They set a “buy” rating and a $37.00 target price on the stock. Zacks Investment Research lowered Evolus from a “hold” rating to a “sell” rating in a research report on Tuesday, February 5th. Mizuho lifted their target price on Evolus from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Tuesday, March 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Evolus in a research report on Tuesday, March 19th. Finally, SunTrust Banks assumed coverage on Evolus in a research report on Wednesday, March 20th. They set a “buy” rating and a $30.00 target price on the stock. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $30.71.

Shares of NASDAQ EOLS traded down $0.30 during midday trading on Tuesday, reaching $22.60. 433,860 shares of the company’s stock were exchanged, compared to its average volume of 1,221,445. Evolus has a 52-week low of $6.75 and a 52-week high of $39.50. The firm has a market cap of $619.30 million, a price-to-earnings ratio of -14.38 and a beta of 5.40.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN lifted its stake in shares of Evolus by 860.3% in the third quarter. Wells Fargo & Company MN now owns 5,944 shares of the company’s stock valued at $110,000 after buying an additional 5,325 shares during the period. IFP Advisors Inc increased its holdings in shares of Evolus by 239.6% in the fourth quarter. IFP Advisors Inc now owns 8,490 shares of the company’s stock valued at $101,000 after purchasing an additional 5,990 shares in the last quarter. Rhumbline Advisers acquired a new stake in shares of Evolus in the fourth quarter valued at approximately $129,000. TIAA CREF Investment Management LLC increased its holdings in shares of Evolus by 51.2% in the third quarter. TIAA CREF Investment Management LLC now owns 12,259 shares of the company’s stock valued at $228,000 after purchasing an additional 4,151 shares in the last quarter. Finally, Man Group plc acquired a new stake in shares of Evolus in the third quarter valued at approximately $232,000. Institutional investors and hedge funds own 19.82% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Story: How is a buy-side analyst different from a sell-side analyst?

Get a free copy of the Zacks research report on Evolus (EOLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.